Initially, 20 mL (40 mg omeprazole) of SOS via nasogastric tube, followed by 20 mL (40 mg) 6—8 hours later, then 10 mL (20 mg) daily thereafter. Administer SOS via tube and follow with 5—10 mL of water; clamp the tube for 1—2 hours after each administration. Efficacy, safety, and cost of SOS was evaluated in a prospective, open-label study of mechanically ventilated, critically ill patients with at least 1 other risk factor for stress-related mucosal damage. In this study, none of the 65 patients receiving SOS developed new clinically significant upper GI bleeds, bleeding diminished in 4 of 5 patients (bleeding prior to study entry) within 18 hours, and bleeding stopped in all patients within 36 hours.
Since September 2012, the marketing licence in the UK has been held by Flynn Pharma Ltd, of Dublin, Ireland , and the product, although identical, has been called Phenytoin Sodium xx mg Flynn Hard Capsules. (The xx mg in the name refers to the strength—for example 'Phenytoin sodium 25 mg Flynn Hard Capsules').  The capsules are still made by Pfizer 's Goedecke subsidiary's plant in Freiburg , Germany and they still have Epanutin printed on them.  After Pfizer's sale of the UK marketing licence to Flynn Pharma, the price of a 28-pack of 25 mg phenytoin sodium capsules marked Epanutin rose from 66p (about $) to £ (about $). Capsules of other strengths also went up in price by the same factor—2384%,  costing the UK's National Health Service an extra £43 million (about $ million) a year.  The companies were referred to the Competition and Markets Authority who found that they had exploited their dominant position in the market to charge “excessive and unfair” prices. 
The safety of DAKTARIN Oral Gel was evaluated in 111 patients with oral candidiasis or oral mycoses who participated in 5 clinical trials. Of these 111 patients, 88 were adults with oral candidiasis or oral mycoses who participated in 1 randomised, active-controlled, double-blind clinical trial and 3 open-label clinical trials. The other 23 patients were paediatric patients with oral candidiasis who participated in 1 randomised, active-controlled, open-label clinical trial in paediatric patients (aged ≤1 month to years). These patients took at least one dose of DAKTARIN Oral Gel and provided safety data.